Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAVCR2 | Q8TDQ0 | 17/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | XDH | P47989 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL404656 | 0.88 | HAVCR2 (0.75) | HAVCR2HSD17B10TP53SMN1; SMN2RXFP1 | |
| SCHEMBL405565 | 0.86 | HAVCR2 (1.00) | HAVCR2HSD17B10 | |
| SCHEMBL31167546 | 0.86 | HAVCR2 (0.80) | HAVCR2HSD17B10XDH | |
| SCHEMBL405740 | 0.86 | HAVCR2 (0.71) | HAVCR2HSD17B10XDH | |
| SCHEMBL462802 | 0.82 | HAVCR2 (0.67) | HAVCR2HSD17B10XDH | |
| SCHEMBL11090906 | 0.82 | HAVCR2 (0.53) | HAVCR2HSD17B10TP53SMN1; SMN2RXFP1 | |
| SCHEMBL9258113 | 0.82 | HAVCR2 (0.66) | HAVCR2HSD17B10XDH | |
| SCHEMBL10924896 | 0.82 | HAVCR2 (1.00) | HAVCR2HSD17B10TP53SMN1; SMN2RXFP1 | |
| SCHEMBL404463 | 0.79 | HAVCR2 (0.71) | HAVCR2HSD17B10 | |
| SCHEMBL405538 | 0.79 | HAVCR2 (0.63) | HAVCR2HSD17B10XDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | ALCON RESEARCH, LTD (US) | 2012-03-15 | — | — | US | disclosed |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | KALYPSYS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065187-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | HAVCR2 84/4885HSD17B10 3443/4885TP53 3565/4885 |
| US-20110257137-A1 | HETEROCYCLIC INHIBITORS OF HISTAMINE RECEPTORS FOR THE TREATMENT OF DISEASE | HRH4, HRH3, HRH2 | HAVCR2 84/4885HSD17B10 3443/4885TP53 3565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.